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Abstract In the novel WHO classification 2008, the
classification of aggressive B-cell lymphoma has been
revised for several categories with the aim to define “clean”
entities. Within large B-cell lymphoma, a few distinct
clinico-pathological entities have been recognized with more
clinically defined entities than pathologically defined ones.
The majority of known morphological variations were not
considered to merit more than classification as a variant of
DLBCL, not otherwise specified. Specifically, a biological
subgrouping of DLBCL on the basis of molecular (activated
B-cell versus germinal center B-cell) or immunophenotypic
(CD5+) features was felt to be too immature to include at this
stage. The role of EBV in aggressive B-cell lymphoma has
been explored in more depth with the recognition of several
novel and re-defined clinico-pathological entities. Also, in
these diseases, clinical definitions play a very dominant role
in the WHO classification 2008.
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Introduction
Aggressive B-cell lymphomas encompass several categories
within diffuse large B-cell lymphoma (DLBCL), Burkitt
lymphoma (BL), and various morphologically, biologically,
and clinically distinct diseases of large B-cells. Over the past
years, research data on the relationships, overlapping features,
and essential differences between various categories of
aggressive B-cell lymphomas have served as the basis of
discussions to separate new categories or to lump together
othersintheWHOclassification2008[1]. EBV-associated B-
cell lymphoma and overlapping features between DLBCL
and BL on one hand and cHL on the other hand have been a
focus of attention. In this paper, issues in DLBCL and EBV-
associated B-cell lymphoma will be discussed. The issue of
lymphomas with overlapping features between DLBCL and
BL and DLBCL and cHL will be discussed separately.
Diffuse large B-cell lymphoma
Proliferations of large B-cells can be classified in different
ways. Morphology-based classification has been the classi-
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Liège, Belgiumcal approach for pathologists. However, more modern
approaches may focus on biological categories, clinical
categories, or even categories that reflect responsiveness to
therapies. For the WHO classification 2008, clinico-
pathological categories have been separated, and an attempt
has been made to define biological categories. As compared
to the WHO classification 2001, the prior “waste basket” of
neoplastic proliferations of large B-cells has been more
extensively subdivided into biologically homogeneous
entities with the introduction of five new entities and the
promotion of three from variants status of DLBCL to
independent distinct entities in recognition of their biolog-
ical uniqueness (Table 1).
The large group of proliferations of large B-cells is
lumped together as diffuse large B-cell lymphoma, not
otherwise specified in parallel to the nomenclature in
peripheral T-cell lymphoma. In situations where there is
insufficient evidence to justify delineation as a separate
entity, the term “variants”, “subgroups”, and “subtypes” are
used. The variants of DLBCL contain morphologically
remarkable features, but do not represent biologically
distinct groups. It is noteworthy that some believe that the
so-called immunoblastic lymphoma category from previ-
ous classifications merits recognition as a distinct entity
since it includes the activated B-cell (ABC) type DLBCL
and is characterized by a worse prognosis. The only real
importance to define such features is to consciously
highlight the morphological spectrum of the disease and
thereby avoid some pitfalls in daily practice (e.g., T-cell-
rich B-cell lymphoma mistaken for T-cell lymphoma or
the anaplastic variant of DLBCL mistaken for metastatic
carcinoma).
T-cell/histiocyte-rich large B-cell lymphoma (THRBCL)
holds a special position by its morphological overlap and
possible biological relation to nodular lymphocyte predomi-
nant Hodgkin lymphoma (NLPHL). The authors of the
Table 1 Classification of aggressive B-cell lymphomas
WHO classification 2001 WHO classification 2008
Diffuse large B-cell lymphoma Diffuse large B-cell lymphoma, not otherwise specified
Morphological variants Common morphological variants
Centroblastic Centroblastic
Immunoblastic Immunoblastic
Anaplastic Anaplastic
T-cell/histiocyte rich Rare morphological variants
Molecular subgroups
Germinal center B-cell like
Activated B-cell like
Rare variants/immunophenotypic subtypes Immunohistochemical subgroups
Plasmablastic lymphoma CD5-positive DLBCL
DLBCL with expression of full length ALK Germinal center B-cell like
Non-germinal center B-cell like
Diffuse large B-cell lymphoma, subtypes
T-cell/histiocyte-rich large B-cell lymphoma
Primary DLBCL of CNS
Primary cutaneous DLBCL, leg-type
EBV positive DLBCL of the elderly (provisional entity)
Mediastinal (thymic) largeB-cell lymphoma Primary mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma Intravascular large B-cell lymphoma
DLBCL associated with chronic inflammation
Lymphomatoid granulomatosis Lymphomatoid granulomatosis
ALK-positive DLBCL
Plasmablastic lymphoma
Large B-cell lymphoma arisingin HHV8 associated
with multicentric Castleman disease
Primary effusion lymphoma Primary effusion lymphoma
Burkitt lymphoma Burkittlymphoma
Endemic BL EndemicBL
Sporadic BL SporadicBL
Immunodeficiency-associated BL Immunodeficiency-associatedBL
BL with plasmacytoid differentiation
Atypical BL/Burkitt like
Borderline cases
B-cell lymphoma, unclassifiable, with features
between DLBCL and Burkitt lymphoma
B-cell lymphoma, unclassifiable, with features
between DLBCL and classical Hodgkin lymphoma
Data in bold are entities discussed in separate chapters; data in italics are subgroups discussed within larger chapters; data in blue are newly
introduced entities and subgroups
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background of small T-cells and histiocytes in a lymph node
that is otherwise involved in NLPHL as “THRBCL-like
areas” not indicative of transformation to aggressive disease
NLPHL as a variant of DLBCL, while the authors of the
NLPHL chapter leave this issue open and thus it remains
controversial. It is agreed upon, however, that the detection of
only a single nodule with features of NLPHL suffices to
exclude a diagnosis of primary THRBCL, and in this sense,
the definition is much sharper than in the WHO classification
2001.
Molecular and immunophenotypic subgrouping
in DLBCL, NOS
It has been debated if it would be timely to introduce gene-
expression based biological subgrouping of DLBCL in the
WHO classification 2008. In 2000, DLBCL with gene-
expression profiles of germinal center B-cells and activated
B-cell-like were first described. Subsequently, it was found
that both groups carry characteristic genetic aberrations and
yet may be morphologically indistinguishable to a large
extent. Since gene-expression profiling is not generally
available for diagnostic purposes in daily practice, “trans-
lations” to immunohistochemical algorithms have been
defined, including the so-called Hans-algorithm [2]. How-
ever,theimmunophenotypicsubdivisiononlycorrelatestothe
gene-expression subgrouping in around 80% of the cases;
thus, the reproducibility of the immunophenotypic classifica-
tion is suboptimal, and the prognostic impact is conflicting.
Similar considerations regarding a lack of reproducibility and
biological and prognostic impact can apply for the CD5+
DLBCL, considered a immunohistochemical subgroup in the
W H Oc l a s s i f i c a t i o n2 0 0 8[ 3–5]. Therefore, immunohisto-
chemical and molecular subgroups of DLBCL, NOS are only
considered as variants with a similar level of relative (un)
importance as morphologic variants, but not advocated as
separate entities. Indeed, there is no justification to use this
information for treatment stratification and for use in routine
clinical practice. This situation may be quite different in
experimental treatment programs, and it can be expected that
introduction of some form of “biomarker”-based treatment
stratification will find its way into practice in the coming few
years. Up to that time, however, it is debatable whether to
include this type of information in routine pathology reports
withoutextensivecommentsonitsinterpretationforclinicians.
Clinico-pathological subtypes of large B-cell lymphomas
Both in the listing of “DLBCL, subtypes” and the “other
lymphomas of large B-cells”, clinico-pathological subtypes
that may be mostly defined by clinical features are found:
primary DLBCL of CNS, primary cutaneous DLBCL, leg-
type, EBV-positive DLBCL of the elderly, and intravascular
large B-cell lymphoma. Of these, intravascular large B-cell
lymphoma was also described in the WHO classification
2001. The others are newly introduced entities.
Primary DLBCL of CNS has been introduced to describe
primary intracerebral and intraocular DLBCL, excluding
lymphomas of the dura, intravascular large B-cell lympho-
ma, secondary CNS localizations and lymphomas in
immunodeficient patients. Apart from the typical clinical
situation, these lymphomas are mostly distinctive by
biological features related to the immune-privileged char-
acter of the primary site. These include microenvironment
modulation by IL-4, loss of HLA class I and II protein
expression, and immunoglobulin structure (extreme Ig
hypermutation in concert with retention of an open reading
frame) [6]. Identical features are found in lymphomas at
other immune-privileged sites such as testis. Perhaps future
classifications may consider combining primary DLBCL in
the testis together with primary DLBCL of the CNS as a
new entity of DLBCL involving immunoprivileged sites.
Herpes-virus (EBV/HHV8)-related
large B-cell proliferations
Several large B-cell proliferations related to EBV infection
and/or immunodeficiency status have been recognized in
the 2008 WHO classification as separate entities or
introduced as new ones (Table 1).
The common feature of these processes is the association
of an immunodeficiency status with an EBV or HHV-
8 related B-cell neoplasm (Table 2). The three newly
introduced entities (EBV-positive diffuse large B-cell
lymphoma of the elderly, DLBCL associated with chronic
inflammation and large B-cell lymphoma arising in HHV-8-
associated multicentric Castleman disease) depict mainly
the clinical setting in which the lymphoma originated. The
recognition of factors such as age and chronic inflammation
(not only pyothorax-associated) as causes of immunodefi-
ciency in EBV-associated DLBCL in the absence of any
other primary or secondary immune disease prompted the
segregation of these into two clinico-pathological catego-
ries. Although molecular studies have shown that DLBCL
associated with chronic inflammation and nodal diffuse
large B-cell lymphoma have significant different gene-
expression profiles, EBV-positive diffuse large B-cell
lymphoma of the elderly and DLBCL associated with
chronic inflammation have no single morphological or
phenotypical feature that distinguish them from DLBCL
not otherwise specified (NOS). Therefore, the clinico-
pathological correlation is the gold standard in the proper
J Hematopathol (2009) 2:83–87 85diagnosis of these entities. Most cases show a post-germinal
center phenotype, and a subset of them have an immuno-
blast/plasmablast morphology and phenotype, concordantly
with the plasma cell differentiation induced by EBV.
Similar to post-transplant lymphoproliferative disorders,
tumor cells express LMP-1 and EBNA-2 hence a latency
pattern III, known as the growth program. Cells expressing
the EBV growth program are restricted to the naive B-cell
subset in healthy individuals. It might be that in the absence
of immune surveillance, EBV-infected germinal center or
memory B-cells can switch to latency III and undergo
clonal expansion. The expression of the full spectrum of
latent EBV genes indicates an important role for the virus
in driving proliferation of the infected B-cells [7, 8].
Multicentric Castleman disease is associated with HHV8
infection, and this situation may evolve into a specific type
of large B-cell lymphoma, particularly in HIV+ patients.
The B-cell lymphoma occurring in this clinical setting was
initially defined as a plasmablastic lymphoma because the
postulated cell of origin morphologically resembles a
plasmablast. However, the tumor cells are often CD20
positive and represent a naive IgM secreting cell without
somatic hypermutations [9–11]. These cases must be
distinguished from the oral type plasmablastic lymphoma
that is EBV positive and HHV8 negative.
Plasmablastic lymphoma of the oral type was regarded in
the former WHO classification as a subtype of DLBCL
associated with HIV infection. Later descriptions have
reported cases of plasmablastic lymphoma outside of this
clinical setting and even in patients without any known cause
of immunodeficiency [12]. The WHO 2008 classification
has broadened the definition of the previous classification to
other localizations apart from the oral mucosa and also to
other immunodeficiency states other than HIV infection.
Plasmablastic lymphoma presents mostly in extranodal sites
and in the majority of cases is associated with EBV
infection. Tumor cells have immunoblastic morphology with
a mature plasma cell phenotype. Clonal IgH rearrangement
is demonstrable, and the IgH genes may show evidence of
somatic hypermutation or be in an unmutated configuration
[13]. The monotonous morphological appearance of the
majority of these tumors reflects the lack of a T-cell host
response. In these cases, LMP-1 is rarely expressed, and the
most frequent latency pattern is type-I, in which EBNA-1
does not serve as a target for CD8 cytotoxic T lymphocytes
[7]. The lack of co-stimulatory surface molecules helps the
Table 2 Features of Herpes-virus-related lymphoid neoplasms
EBV-positive
diffuse large B-
cell lymphoma
of the elderly
DLBCL associated with
chronic inflammation
Lymphomatous
granulomatosis
Plasmablastic
lymphoma
Primary
effusion
lymphoma
Large B-cell lympho-
ma arising in HHV8-
associated multicentric
Castleman disease
EBV positivity 100% 100% 60–75% 100% 90% 0%
HHV8 positivity –– –– 100% 100%
Characteristic
morphological
features
–– Inflammatory
background,
angiotropic, and
angiodestructive
Immunoblastic/
plasmablastic
Immunoblastic/
plasmablastic
Plasmablastic,
perifollicular
arrangement
Characteristic
immunophenotype
–– –CD20−,P A X 5 −,
CD138+,
MUM1+
CD20−,
CD79a−,I g −,
CD138+,
EMA+,
CD30+
CD20+, Ig+
Characteristic
clinical features
Age >50 Long-standing chronic
inflammatory process
(>10 years) primary
extranodal (pleural
cavity)
Primary
extranodal
(pulmonary,
brain, kidney,
skin)
Oral cavity,
other
extranodal
sites
Pleural,
pericardial,
peritoneal
cavity
Multicentric Castleman
disease
Primary
immunodeficiency
–– + (Wiskott–
Aldrich
syndrome)
–––
HIV –– ++ + +
Organ transplant –– ++ + –
Other iatogenic
immunodeficiencies
–– ++ + –
Elderly + –– + + (in HHV8
endemic
areas)
+ (in HHV8 endemic
areas)
86 J Hematopathol (2009) 2:83–87tumor cells to escape from immunological recognition, but
also leaves as an open question the role of EBV in the
pathogenesis of these lymphomas.
All the entities described above are characterized by a very
aggressive behavior and short survival regardless of Interna-
tional Prognostic Index and stage at diagnosis. The immuno-
suppressed state in the most part of patients contributes to the
poor clinical course. Additionally, downregulation of HLA
class I expression [14] and activation of the IL-6 [15]
receptor signaling pathway have been described in some
cases as mechanisms of escape from host cytotoxic T
lymphocytes. This is not unlike the mechanisms by which
DLBCL of immunoprivileged sites maintain immune-escape.
Previous attempts to segregate different hematolymphoid
entities usually started with the observation of morpholog-
ical features characteristic of a disease and then a later
description of a cytogenetic or molecular alteration that now
are part of the definition of the entity. In DLBCL, the
morphologic, phenotypic, and clinical heterogeneity has led
the efforts to segregate different subgroups. In the last WHO
classification, several entities with overlapping morpholog-
ical features have been separated based on clinical features;
molecular and cytogenetic studies are required to better
understand the biological basis of these entities.
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